Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
The price of NewAmsterdam Pharma Company NV (NASDAQ: NAMS) closed at $23.34 in the last session, down -0.13% from day before closing price of $23.37. In other words, the price has decreased by -$0.13 from its previous closing price. On the day, 1.44 million shares were traded. NAMS stock price reached its highest trading level at $23.77 during the session, while it also had its lowest trading level at $23.14.
Ratios:
We take a closer look at NAMS’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 8.08 and its Current Ratio is at 8.08. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, H.C. Wainwright on December 30, 2024, initiated with a Buy rating and assigned the stock a target price of $48.
On March 14, 2024, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $35.Scotiabank initiated its Sector Outperform rating on March 14, 2024, with a $35 target price.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Mar 04 ’25 when Topper James N bought 4,005 shares for $21.02 per share. The transaction valued at 84,203 led to the insider holds 3,012,434 shares of the business.
Kooij Louise Frederika sold 150,000 shares of NAMS for $3,055,500 on Mar 04 ’25. The Chief Accounting Officer now owns 15,000 shares after completing the transaction at $20.37 per share. On Mar 04 ’25, another insider, Kooij Louise Frederika, who serves as the Officer of the company, bought 150,000 shares for $20.27 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, NAMS now has a Market Capitalization of 2563152128 and an Enterprise Value of 1729405696. For the stock, the TTM Price-to-Sale (P/S) ratio is 56.26 while its Price-to-Book (P/B) ratio in mrq is 3.33. Its current Enterprise Value per Revenue stands at 37.956 whereas that against EBITDA is -9.816.
Stock Price History:
The Beta on a monthly basis for NAMS is -0.09, which has changed by 0.05850339 over the last 52 weeks, in comparison to a change of 0.09589827 over the same period for the S&P500. Over the past 52 weeks, NAMS has reached a high of $27.29, while it has fallen to a 52-week low of $15.19. The 50-Day Moving Average of the stock is 5.72%, while the 200-Day Moving Average is calculated to be 17.03%.
Shares Statistics:
According to the various share statistics, NAMS traded on average about 817.89K shares per day over the past 3-months and 1555560 shares per day over the past 10 days. A total of 108.06M shares are outstanding, with a floating share count of 58.10M. Insiders hold about 47.09% of the company’s shares, while institutions hold 47.84% stake in the company. Shares short for NAMS as of 1740700800 were 3040999 with a Short Ratio of 3.72, compared to 1738281600 on 2798784. Therefore, it implies a Short% of Shares Outstanding of 3040999 and a Short% of Float of 4.17.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
